Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.48 |
| ▸ | ATM | Q13315 | 5/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | GLA | P06280 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292757 | 0.90 | PRKCZ (0.62) | CA1CA2PRKCZEGFRERBB2 | |
| SCHEMBL6293056 | 0.87 | CA1 (0.56) | CA1CA2PRKCZEGFRERBB2 | |
| SCHEMBL7586677 | 0.80 | MEN1 (0.53) | CA1CA2PRKCZEGFRERBB2 | |
| SCHEMBL31429970 | 0.79 | EGFR (0.74) | CA1CA2EGFRERBB2MEN1 | |
| SCHEMBL6293086 | 0.79 | PRKCZ (0.72) | PRKCZEGFRERBB2MEN1KMT2A | |
| SCHEMBL2687295 | 0.76 | EGFR (0.78) | CA1CA2PRKCZEGFRERBB2 | |
| SCHEMBL5805189 | 0.75 | MAPT (0.64) | CA1CA2PRKCZEGFRERBB2 | |
| SCHEMBL27955200 | 0.71 | MEN1 (0.77) | CA1CA2PRKCZEGFRERBB2 | |
| SCHEMBL23052404 | 0.70 | MEN1 (0.73) | CA1CA2PRKCZEGFRERBB2 | |
| SCHEMBL395608 | 0.70 | MEN1 (0.73) | CA1CA2PRKCZEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2003-05-01 | — | — | US | claimed |
| WO-2002089799-A2 | USE OF DIHYDROPYRAZOLES TO INCREASE ERYTHROPOIETIN AND VASCULARI ZATION | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-14 | — | — | WO | claimed |
| US-20050090532-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2005-04-28 | — | — | US | disclosed |
| US-6878729-B2 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2003-05-01 | — | — | US | disclosed |
| WO-2002089799-A2 | USE OF DIHYDROPYRAZOLES TO INCREASE ERYTHROPOIETIN AND VASCULARI ZATION | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090532-A1 | Medicinal uses of dihydropyrazoles | EPOR, VEGFA, FLT4 | CA1 3298/4885CA2 2657/4885PRKCZ 1994/4885 |
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | EPOR, VEGFA, TEK | CA1 3038/4885CA2 2488/4885PRKCZ 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.